The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
SARS-CoV-2 IgG (RBD) ELISA-Global Market Insights and Sales Trends 2025
Synopsis
The global SARS-CoV-2 IgG (RBD) ELISA market size is expected to reach US$ million by 2029, growing at a CAGR of % from 2023 to 2029. The market is mainly driven by the significant applications of SARS-CoV-2 IgG (RBD) ELISA in various end use industries. The expanding demands from the Hospital, Clinic and Disease control and prevention system,, are propelling SARS-CoV-2 IgG (RBD) ELISA market. ELISA Sets, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the ELISA Kits segment is estimated at % CAGR for the next seven-year period.
Asia Pacific shows high growth potential for SARS-CoV-2 IgG (RBD) ELISA market, driven by demand from China, the second largest economy with some signs of stabilising, the SARS-CoV-2 IgG (RBD) ELISA market in China is forecast to reach US$ million by 2029, trailing a CAGR of % over the 2023-2029 period, while the U.S. market will reach US$ million by 2029, exhibiting a CAGR of % during the same period.
Report Objectives
This report provides market insight on the different segments, by players, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for SARS-CoV-2 IgG (RBD) ELISA, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global SARS-CoV-2 IgG (RBD) ELISA market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global SARS-CoV-2 IgG (RBD) ELISA market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, SARS-CoV-2 IgG (RBD) ELISA sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of SARS-CoV-2 IgG (RBD) ELISA covered in this report include R&D Systems, Thermo Fisher Scientific, Ortho Clinical Diagnostics, BD Biosciences, ZEUS Scientific, Bio-Rad Laboratories, ALPCO, Enzo Life Sciences and BioMérieux, etc.
The global SARS-CoV-2 IgG (RBD) ELISA market report caters to various stakeholders in this industry including investors, suppliers, product players, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
R&D Systems
Thermo Fisher Scientific
Ortho Clinical Diagnostics
BD Biosciences
ZEUS Scientific
Bio-Rad Laboratories
ALPCO
Enzo Life Sciences
BioMérieux
LOEWE Biochemica
Shenzhen YHLO Biotech
LG
Global SARS-CoV-2 IgG (RBD) ELISA market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global SARS-CoV-2 IgG (RBD) ELISA market, Segment by Type:
ELISA Sets
ELISA Kits
Global SARS-CoV-2 IgG (RBD) ELISA market, by Application
Hospital
Clinic
Disease control and prevention system
Core Chapters
Chapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter Two: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter Three: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter Four: Detailed analysis of SARS-CoV-2 IgG (RBD) ELISA companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Five: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter Six, Seven, Eight, Nine and Ten: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
Chapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Research Finding/Conclusion
The global SARS-CoV-2 IgG (RBD) ELISA market size is expected to reach US$ million by 2029, growing at a CAGR of % from 2023 to 2029. The market is mainly driven by the significant applications of SARS-CoV-2 IgG (RBD) ELISA in various end use industries. The expanding demands from the Hospital, Clinic and Disease control and prevention system,, are propelling SARS-CoV-2 IgG (RBD) ELISA market. ELISA Sets, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the ELISA Kits segment is estimated at % CAGR for the next seven-year period.
Asia Pacific shows high growth potential for SARS-CoV-2 IgG (RBD) ELISA market, driven by demand from China, the second largest economy with some signs of stabilising, the SARS-CoV-2 IgG (RBD) ELISA market in China is forecast to reach US$ million by 2029, trailing a CAGR of % over the 2023-2029 period, while the U.S. market will reach US$ million by 2029, exhibiting a CAGR of % during the same period.
Report Objectives
This report provides market insight on the different segments, by players, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for SARS-CoV-2 IgG (RBD) ELISA, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global SARS-CoV-2 IgG (RBD) ELISA market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global SARS-CoV-2 IgG (RBD) ELISA market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, SARS-CoV-2 IgG (RBD) ELISA sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of SARS-CoV-2 IgG (RBD) ELISA covered in this report include R&D Systems, Thermo Fisher Scientific, Ortho Clinical Diagnostics, BD Biosciences, ZEUS Scientific, Bio-Rad Laboratories, ALPCO, Enzo Life Sciences and BioMérieux, etc.
The global SARS-CoV-2 IgG (RBD) ELISA market report caters to various stakeholders in this industry including investors, suppliers, product players, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
R&D Systems
Thermo Fisher Scientific
Ortho Clinical Diagnostics
BD Biosciences
ZEUS Scientific
Bio-Rad Laboratories
ALPCO
Enzo Life Sciences
BioMérieux
LOEWE Biochemica
Shenzhen YHLO Biotech
LG
Global SARS-CoV-2 IgG (RBD) ELISA market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global SARS-CoV-2 IgG (RBD) ELISA market, Segment by Type:
ELISA Sets
ELISA Kits
Global SARS-CoV-2 IgG (RBD) ELISA market, by Application
Hospital
Clinic
Disease control and prevention system
Core Chapters
Chapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter Two: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter Three: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter Four: Detailed analysis of SARS-CoV-2 IgG (RBD) ELISA companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Five: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter Six, Seven, Eight, Nine and Ten: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
Chapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Research Finding/Conclusion
Index1 Market Overview of SARS-CoV-2 IgG (RBD) ELISA
1.1 SARS-CoV-2 IgG (RBD) ELISA Market Overview
1.1.1 SARS-CoV-2 IgG (RBD) ELISA Product Scope
1.1.2 SARS-CoV-2 IgG (RBD) ELISA Market Status and Outlook
1.2 Global SARS-CoV-2 IgG (RBD) ELISA Market Size Overview by Region 2018 VS 2022 VS 2029
1.3 Global SARS-CoV-2 IgG (RBD) ELISA Market Size by Region (2018-2029)
1.4 Global SARS-CoV-2 IgG (RBD) ELISA Historic Market Size by Region (2018-2023)
1.5 Global SARS-CoV-2 IgG (RBD) ELISA Market Size Forecast by Region (2024-2029)
1.6 Key Regions, SARS-CoV-2 IgG (RBD) ELISA Market Size (2018-2029)
1.6.1 North America SARS-CoV-2 IgG (RBD) ELISA Market Size (2018-2029)
1.6.2 Europe SARS-CoV-2 IgG (RBD) ELISA Market Size (2018-2029)
1.6.3 Asia-Pacific SARS-CoV-2 IgG (RBD) ELISA Market Size (2018-2029)
1.6.4 Latin America SARS-CoV-2 IgG (RBD) ELISA Market Size (2018-2029)
1.6.5 Middle East & Africa SARS-CoV-2 IgG (RBD) ELISA Market Size (2018-2029)
2 SARS-CoV-2 IgG (RBD) ELISA Market by Type
2.1 Introduction
2.1.1 ELISA Sets
2.1.2 ELISA Kits
2.2 Global SARS-CoV-2 IgG (RBD) ELISA Market Size by Type: 2018 VS 2022 VS 2029
2.2.1 Global SARS-CoV-2 IgG (RBD) ELISA Historic Market Size by Type (2018-2023)
2.2.2 Global SARS-CoV-2 IgG (RBD) ELISA Forecasted Market Size by Type (2024-2029)
2.3 Key Regions Market Size by Type
2.3.1 North America SARS-CoV-2 IgG (RBD) ELISA Revenue Breakdown by Type (2018-2029)
2.3.2 Europe SARS-CoV-2 IgG (RBD) ELISA Revenue Breakdown by Type (2018-2029)
2.3.3 Asia-Pacific SARS-CoV-2 IgG (RBD) ELISA Revenue Breakdown by Type (2018-2029)
2.3.4 Latin America SARS-CoV-2 IgG (RBD) ELISA Revenue Breakdown by Type (2018-2029)
2.3.5 Middle East and Africa SARS-CoV-2 IgG (RBD) ELISA Revenue Breakdown by Type (2018-2029)
3 SARS-CoV-2 IgG (RBD) ELISA Market Overview by Application
3.1 Introduction
3.1.1 Hospital
3.1.2 Clinic
3.1.3 Disease control and prevention system
3.2 Global SARS-CoV-2 IgG (RBD) ELISA Market Size by Application: 2018 VS 2022 VS 2029
3.2.1 Global SARS-CoV-2 IgG (RBD) ELISA Historic Market Size by Application (2018-2023)
3.2.2 Global SARS-CoV-2 IgG (RBD) ELISA Forecasted Market Size by Application (2024-2029)
3.3 Key Regions Market Size by Application
3.3.1 North America SARS-CoV-2 IgG (RBD) ELISA Revenue Breakdown by Application (2018-2029)
3.3.2 Europe SARS-CoV-2 IgG (RBD) ELISA Revenue Breakdown by Application (2018-2029)
3.3.3 Asia-Pacific SARS-CoV-2 IgG (RBD) ELISA Revenue Breakdown by Application (2018-2029)
3.3.4 Latin America SARS-CoV-2 IgG (RBD) ELISA Revenue Breakdown by Application (2018-2029)
3.3.5 Middle East and Africa SARS-CoV-2 IgG (RBD) ELISA Revenue Breakdown by Application (2018-2029)
4 SARS-CoV-2 IgG (RBD) ELISA Competition Analysis by Players
4.1 Global SARS-CoV-2 IgG (RBD) ELISA Market Size by Players (2018-2023)
4.2 Global Top Players by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in SARS-CoV-2 IgG (RBD) ELISA as of 2022)
4.3 Date of Key Players Enter into SARS-CoV-2 IgG (RBD) ELISA Market
4.4 Global Top Players SARS-CoV-2 IgG (RBD) ELISA Headquarters and Area Served
4.5 Key Players SARS-CoV-2 IgG (RBD) ELISA Product Solution and Service
4.6 Competitive Status
4.6.1 SARS-CoV-2 IgG (RBD) ELISA Market Concentration Rate
4.6.2 Mergers & Acquisitions, Expansion Plans
5 Company (Top Players) Profiles
5.1 R&D Systems
5.1.1 R&D Systems Profile
5.1.2 R&D Systems Main Business
5.1.3 R&D Systems SARS-CoV-2 IgG (RBD) ELISA Products, Services and Solutions
5.1.4 R&D Systems SARS-CoV-2 IgG (RBD) ELISA Revenue (US$ Million) & (2018-2023)
5.1.5 R&D Systems Recent Developments
5.2 Thermo Fisher Scientific
5.2.1 Thermo Fisher Scientific Profile
5.2.2 Thermo Fisher Scientific Main Business
5.2.3 Thermo Fisher Scientific SARS-CoV-2 IgG (RBD) ELISA Products, Services and Solutions
5.2.4 Thermo Fisher Scientific SARS-CoV-2 IgG (RBD) ELISA Revenue (US$ Million) & (2018-2023)
5.2.5 Thermo Fisher Scientific Recent Developments
5.3 Ortho Clinical Diagnostics
5.3.1 Ortho Clinical Diagnostics Profile
5.3.2 Ortho Clinical Diagnostics Main Business
5.3.3 Ortho Clinical Diagnostics SARS-CoV-2 IgG (RBD) ELISA Products, Services and Solutions
5.3.4 Ortho Clinical Diagnostics SARS-CoV-2 IgG (RBD) ELISA Revenue (US$ Million) & (2018-2023)
5.3.5 BD Biosciences Recent Developments
5.4 BD Biosciences
5.4.1 BD Biosciences Profile
5.4.2 BD Biosciences Main Business
5.4.3 BD Biosciences SARS-CoV-2 IgG (RBD) ELISA Products, Services and Solutions
5.4.4 BD Biosciences SARS-CoV-2 IgG (RBD) ELISA Revenue (US$ Million) & (2018-2023)
5.4.5 BD Biosciences Recent Developments
5.5 ZEUS Scientific
5.5.1 ZEUS Scientific Profile
5.5.2 ZEUS Scientific Main Business
5.5.3 ZEUS Scientific SARS-CoV-2 IgG (RBD) ELISA Products, Services and Solutions
5.5.4 ZEUS Scientific SARS-CoV-2 IgG (RBD) ELISA Revenue (US$ Million) & (2018-2023)
5.5.5 ZEUS Scientific Recent Developments
5.6 Bio-Rad Laboratories
5.6.1 Bio-Rad Laboratories Profile
5.6.2 Bio-Rad Laboratories Main Business
5.6.3 Bio-Rad Laboratories SARS-CoV-2 IgG (RBD) ELISA Products, Services and Solutions
5.6.4 Bio-Rad Laboratories SARS-CoV-2 IgG (RBD) ELISA Revenue (US$ Million) & (2018-2023)
5.6.5 Bio-Rad Laboratories Recent Developments
5.7 ALPCO
5.7.1 ALPCO Profile
5.7.2 ALPCO Main Business
5.7.3 ALPCO SARS-CoV-2 IgG (RBD) ELISA Products, Services and Solutions
5.7.4 ALPCO SARS-CoV-2 IgG (RBD) ELISA Revenue (US$ Million) & (2018-2023)
5.7.5 ALPCO Recent Developments
5.8 Enzo Life Sciences
5.8.1 Enzo Life Sciences Profile
5.8.2 Enzo Life Sciences Main Business
5.8.3 Enzo Life Sciences SARS-CoV-2 IgG (RBD) ELISA Products, Services and Solutions
5.8.4 Enzo Life Sciences SARS-CoV-2 IgG (RBD) ELISA Revenue (US$ Million) & (2018-2023)
5.8.5 Enzo Life Sciences Recent Developments
5.9 BioMérieux
5.9.1 BioMérieux Profile
5.9.2 BioMérieux Main Business
5.9.3 BioMérieux SARS-CoV-2 IgG (RBD) ELISA Products, Services and Solutions
5.9.4 BioMérieux SARS-CoV-2 IgG (RBD) ELISA Revenue (US$ Million) & (2018-2023)
5.9.5 BioMérieux Recent Developments
5.10 LOEWE Biochemica
5.10.1 LOEWE Biochemica Profile
5.10.2 LOEWE Biochemica Main Business
5.10.3 LOEWE Biochemica SARS-CoV-2 IgG (RBD) ELISA Products, Services and Solutions
5.10.4 LOEWE Biochemica SARS-CoV-2 IgG (RBD) ELISA Revenue (US$ Million) & (2018-2023)
5.10.5 LOEWE Biochemica Recent Developments
5.11 Shenzhen YHLO Biotech
5.11.1 Shenzhen YHLO Biotech Profile
5.11.2 Shenzhen YHLO Biotech Main Business
5.11.3 Shenzhen YHLO Biotech SARS-CoV-2 IgG (RBD) ELISA Products, Services and Solutions
5.11.4 Shenzhen YHLO Biotech SARS-CoV-2 IgG (RBD) ELISA Revenue (US$ Million) & (2018-2023)
5.11.5 Shenzhen YHLO Biotech Recent Developments
5.12 LG
5.12.1 LG Profile
5.12.2 LG Main Business
5.12.3 LG SARS-CoV-2 IgG (RBD) ELISA Products, Services and Solutions
5.12.4 LG SARS-CoV-2 IgG (RBD) ELISA Revenue (US$ Million) & (2018-2023)
5.12.5 LG Recent Developments
6 North America
6.1 North America SARS-CoV-2 IgG (RBD) ELISA Market Size by Country (2018-2029)
6.2 United States
6.3 Canada
7 Europe
7.1 Europe SARS-CoV-2 IgG (RBD) ELISA Market Size by Country (2018-2029)
7.2 Germany
7.3 France
7.4 U.K.
7.5 Italy
7.6 Russia
7.7 Nordic Countries
7.8 Rest of Europe
8 Asia-Pacific
8.1 Asia-Pacific SARS-CoV-2 IgG (RBD) ELISA Market Size by Region (2018-2029)
8.2 China
8.3 Japan
8.4 South Korea
8.5 Southeast Asia
8.6 India
8.7 Australia
8.8 Rest of Asia-Pacific
9 Latin America
9.1 Latin America SARS-CoV-2 IgG (RBD) ELISA Market Size by Country (2018-2029)
9.2 Mexico
9.3 Brazil
9.4 Rest of Latin America
10 Middle East & Africa
10.1 Middle East & Africa SARS-CoV-2 IgG (RBD) ELISA Market Size by Country (2018-2029)
10.2 Turkey
10.3 Saudi Arabia
10.4 UAE
10.5 Rest of Middle East & Africa
11 SARS-CoV-2 IgG (RBD) ELISA Market Dynamics
11.1 SARS-CoV-2 IgG (RBD) ELISA Industry Trends
11.2 SARS-CoV-2 IgG (RBD) ELISA Market Drivers
11.3 SARS-CoV-2 IgG (RBD) ELISA Market Challenges
11.4 SARS-CoV-2 IgG (RBD) ELISA Market Restraints
12 Research Finding /Conclusion
13 Methodology and Data Source
13.1 Methodology/Research Approach
13.1.1 Research Programs/Design
13.1.2 Market Size Estimation
13.1.3 Market Breakdown and Data Triangulation
13.2 Data Source
13.2.1 Secondary Sources
13.2.2 Primary Sources
13.3 Disclaimer
13.4 Author List
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
